Antibodies

13 Sep 2022 Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
13 Sep 2022 Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
13 Sep 2022 First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO
13 Sep 2022 Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
13 Sep 2022 Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
12 Sep 2022 Cytovia Therapeutics Presents New Preclinical Data for Its GPC3 Flex-NK™ Cell Engager Antibody in Combination With Natural Killer Cells at ESMO 2022 in Paris
12 Sep 2022 Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
12 Sep 2022 Imfinzi plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
12 Sep 2022 Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
11 Sep 2022 Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
11 Sep 2022 Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
11 Sep 2022 Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
11 Sep 2022 Imfinzi and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
11 Sep 2022 Novartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial
11 Sep 2022 Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
11 Sep 2022 Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
11 Sep 2022 Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elev
11 Sep 2022 DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
11 Sep 2022 Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022
11 Sep 2022 CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
09 Sep 2022 OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors
09 Sep 2022 Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
09 Sep 2022 Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials
09 Sep 2022 Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
09 Sep 2022 Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top